Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks.

The purpose of this consensus statement is to offer primary care providers (including physicians, nurse practitioners, and physician assistants) a practical, evidence-based clinical tool for achieving blood pressure goals in African American patients. The need for specific recommendations for African Americans is highlighted by compelling evidence of a higher prevalence of hypertension and poorer cardiovascular and renal outcomes in this group than in white Americans. African Americans have disturbingly higher rates of cardiovascular mortality, stroke, hypertension-related heart disease, congestive heart failure, type 2 diabetes mellitus, hypertensive nephropathy, and end-stage renal disease (ESRD). 1,2 .

[1]  Clinical Practice Recommendations 2005. , 2005, Diabetes care.

[2]  A. Manley.  Physical Activity And Health: A Report Of The Surgeon General , 2004 .

[3]  P. Raskin,et al.  Treatment of hypertension in adults with diabetes. , 2003, Diabetes care.

[4]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[5]  S. Oparil,et al.  Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. , 2003, Journal of the American College of Cardiology.

[6]  B. Davis,et al.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.

[7]  Tom Greene,et al.  Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. , 2002, JAMA.

[8]  Carl J Pepine,et al.  ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients , 2002, Journal of the American College of Cardiology.

[9]  Steven Snapinn,et al.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol , 2002, The Lancet.

[10]  M. Nieminen,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[11]  P. Mehler,et al.  Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. , 2002, Kidney international.

[12]  P. Lapuerta,et al.  Physician-related barriers to the effective management of uncontrolled hypertension. , 2002, Archives of internal medicine.

[13]  M. Mariani,et al.  Microalbuminuria, an integrated marker of cardiovascular risk in essential hypertension , 2002, Journal of Human Hypertension.

[14]  E. Lewis,et al.  Renoprotective effects of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes , 2002 .

[15]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy , 2002 .

[16]  R. Grimm,et al.  New salt-sensitivity metrics: variability-adjusted blood pressure change and the urinary sodium-to-creatinine ratio. , 2002, Ethnicity & disease.

[17]  G. Bakris,et al.  Type 2 Diabetes: RENAAL and IDNT—The Emergence of New Treatment Options , 2002, Journal of clinical hypertension.

[18]  Treatment of hypertension in adults with diabetes. , 2002, Diabetes care.

[19]  Sudha Seshadri,et al.  Antecedent Blood Pressure and Risk of Cardiovascular Disease: The Framingham Heart Study , 2002, Circulation.

[20]  J. Cohn,et al.  A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. , 2001, The New England journal of medicine.

[21]  F. Torres,et al.  Nitrendipine and Enalapril Combination Therapy in Mild to Moderate Hypertension: Assessment of Dose-Response Relationship by a Clinical Trial of Factorial Design , 2001, Journal of cardiovascular pharmacology.

[22]  Daniel Levy,et al.  Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study , 2001, The Lancet.

[23]  A. Gavazzi,et al.  [Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomized trial]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[24]  M. Woodward,et al.  Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack , 2001 .

[25]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[26]  H. Parving,et al.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. , 2001, The New England journal of medicine.

[27]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[28]  C. Hennekens,et al.  Black-White Inequalities in Mortality and Life Expectancy, 1933–1999: Implications for Healthy People 2010 , 2001, Public health reports (1974).

[29]  Erik G. Cohen,et al.  Changing Trends in Angioedema , 2001, The Annals of otology, rhinology, and laryngology.

[30]  W. Kraus,et al.  Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension. , 2001, Clinical therapeutics.

[31]  D. Schlundt,et al.  Evaluation of the insulin resistance syndrome in 5- to 10-year-old overweight/obese African-American children. , 2001, Diabetes care.

[32]  R. D'Agostino,et al.  Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. , 2001, JAMA.

[33]  M. Weir,et al.  Valsartan alone or with a diuretic or ACE inhibitor as treatment for African American hypertensives: relation to salt intake. , 2001, American journal of hypertension.

[34]  H. Parving,et al.  Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. , 2001, Kidney international.

[35]  J. Douglas,et al.  The African American Study of Kidney Disease and Hypertension (AASK): New Findings , 2001, Journal of clinical hypertension.

[36]  Keith C. Norris,et al.  Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. , 2001, JAMA.

[37]  J. McGill,et al.  Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. , 2001, Clinical therapeutics.

[38]  D. Grobbee,et al.  Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity , 2001, Journal of internal medicine.

[39]  T. Lumley,et al.  Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: the cardiovascular health study. , 2001, Archives of internal medicine.

[40]  H. Dargie,et al.  Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial , 2001, The Lancet.

[41]  R. Schwartz.  Racial profiling in medical research. , 2001, The New England journal of medicine.

[42]  M. Domanski,et al.  Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. , 2001, The New England journal of medicine.

[43]  C. Yancy,et al.  Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. , 2001, The New England journal of medicine.

[44]  Alan C. Wilson,et al.  Effects of reduced sodium intake on hypertension control in older individuals: results from the Trial of Nonpharmacologic Interventions in the Elderly (TONE). , 2001, Archives of internal medicine.

[45]  G. Bray,et al.  Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet , 2001 .

[46]  N. Milas,et al.  Long-Term Weight Loss and Changes in Blood Pressure: Results of the Trials of Hypertension Prevention, Phase II , 2001, Annals of Internal Medicine.

[47]  J. McGill,et al.  Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertension , 2001, Clinical cardiology.

[48]  American Diabetes Association Clinical Practice Recommendations 2001. , 2001, Diabetes care.

[49]  B Neal,et al.  Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials , 2000, The Lancet.

[50]  M. Cooper,et al.  Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study , 2000, BMJ : British Medical Journal.

[51]  S. Oparil,et al.  Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. , 2000, The American journal of cardiology.

[52]  J. Manson,et al.  Systolic and Diastolic Blood Pressure, Pulse Pressure, and Mean Arterial Pressure as Predictors of Cardiovascular Disease Risk in Men , 2000, Hypertension.

[53]  J W Erdman,et al.  AHA Dietary Guidelines: revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. , 2000, Circulation.

[54]  U. Goldbourt,et al.  High blood pressure and diabetes mellitus: are all antihypertensive drugs created equal? , 2000, Archives of Internal Medicine.

[55]  J. W. Schaeffer,et al.  ACC/AHA guidelines for the management of patients with unstable angina and non‐ST segment elevation myocardial infarction: Executive summary and recommendations , 2000, Circulation.

[56]  R. Unwin,et al.  Are calcium antagonists effective in preventing complications of hypertension and progression of renal disease? , 2000, Current opinion in nephrology and hypertension.

[57]  A. Tenenbaum,et al.  Intermediate but not low doses of aspirin can suppress angiotensin-converting enzyme inhibitor-induced cough. , 2000, American journal of hypertension.

[58]  H. Black,et al.  Clinical Advisory Statement. Importance of systolic blood pressure in older Americans. , 2000, Hypertension.

[59]  Barry R. Davis,et al.  Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. , 2000, JAMA.

[60]  R. Schrier,et al.  Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. , 2000, Diabetes care.

[61]  D. Reda,et al.  Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. , 2000, Archives of internal medicine.

[62]  R. Piepho,et al.  Effect of race on hypertension and antihypertensive therapy. , 2000, International journal of clinical pharmacology and therapeutics.

[63]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[64]  W. Kannel,et al.  Elevated systolic blood pressure as a cardiovascular risk factor. , 2000, The American journal of cardiology.

[65]  Philip Greenland,et al.  Prevention Conference V Beyond Secondary Prevention : Identifying the High-Risk Patient for Primary Prevention : Executive Summary , 2000 .

[66]  G. Mensah,et al.  Using Angiotensin Converting Enzyme Inhibitors in African-American Hypertensives: A New Approach to Treating Hypertension and Preventing Target-Organ Damage , 2000, Current medical research and opinion.

[67]  G. Bakris,et al.  SPECIAL REPORT Preserving Renal Function in Adults With Hypertension and Diabetes: A Consensus Approach , 2000 .

[68]  S. Yusuf,et al.  Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators. , 2000, Diabetes care.

[69]  Orton,et al.  EFFECTS ON BLOOD PRESSURE OF REDUCED DIETARY SODIUM AND THE DIETARY APPROACHES TO STOP HYPERTENSION ( DASH ) DIET , 2000 .

[70]  M Ishii,et al.  [The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, and 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension]. , 2000, Nihon rinsho. Japanese journal of clinical medicine.

[71]  Illiam,et al.  THE EFFECT OF NISOLDIPINE AS COMPARED WITH ENALAPRIL ON CARDIOVASCULAR OUTCOMES IN PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES AND HYPERTENSION , 2000 .

[72]  T. Hedner,et al.  Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study , 1999, The Lancet.

[73]  D. Abernethy,et al.  Calcium-antagonist drugs. , 1999, The New England journal of medicine.

[74]  R. Bain,et al.  Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[75]  G. Bakris.  Maximizing Cardiorenal Benefit in the Management of Hypertension: Achieve Blood Pressure Goals. , 1999, Journal of clinical hypertension.

[76]  S M Grundy,et al.  Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. , 1999, Circulation.

[77]  P. Whelton,et al.  Elevated systolic blood pressure and risk of cardiovascular and renal disease: overview of evidence from observational epidemiologic studies and randomized controlled trials. , 1999, American heart journal.

[78]  R. Guthrie,et al.  Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. , 1999, American journal of hypertension.

[79]  K. Ryschon,et al.  Fixed-dose combination vs monotherapy in hypertension: a meta-analysis evaluation , 1999, Journal of Human Hypertension.

[80]  P. Whelton,et al.  Elevated systolic blood pressure as a risk factor for cardiovascular and renal disease. , 1999, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[81]  G. Harshfield,et al.  Racial differences in ambulatory blood pressure monitoring-derived 24 h patterns of blood pressure in adolescents. , 1999, Blood pressure monitoring.

[82]  Sankey V. Williams,et al.  ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Chronic Stable Angina). , 1999, Circulation.

[83]  G. Eknoyan,et al.  Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[84]  C. Bulpitt,et al.  Effects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic Hypertension , 1999 .

[85]  M. Moser.  A critique of the world health organization-international society of hypertension guidelines for the management of hypertension , 1999 .

[86]  A. Forman,et al.  Normotensive salt sensitivity: effects of race and dietary potassium. , 1999, Hypertension.

[87]  M. Cirillo,et al.  Microalbuminuria in nondiabetic adults: relation of blood pressure, body mass index, plasma cholesterol levels, and smoking: The Gubbio Population Study. , 1998, Archives of internal medicine.

[88]  Philip D. Harvey,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.

[89]  R. Holman,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. , 1998 .

[90]  S. Gottlieb,et al.  Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. , 1998, The New England journal of medicine.

[91]  T A Kotchen,et al.  Dietary electrolytes and blood pressure: a statement for healthcare professionals from the American Heart Association Nutrition Committee. , 1998, Circulation.

[92]  Joël Ménard,et al.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.

[93]  D. Levy,et al.  Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.

[94]  J. Wallin,et al.  End-stage renal disease in specific ethnic and racial groups: risk factors and benefits of antihypertensive therapy. , 1998, Archives of internal medicine.

[95]  M. Pahor,et al.  Outcome Results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in Patients With Hypertension and NIDDM , 1998, Diabetes Care.

[96]  R. Eckel,et al.  Obesity and heart disease: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. , 1997, Circulation.

[97]  K. Borch-Johnsen,et al.  Microalbuminuria and its relation to cardiovascular disease and risk factors. A population-based study of 1254 hypertensive individuals , 1997, Journal of Human Hypertension.

[98]  V. Fuster,et al.  Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. , 1997, Circulation.

[99]  F. Cosmi,et al.  Combined therapy with benazepril and amlodipine in the treatment of hypertension inadequately controlled by an ACE inhibitor alone. , 1997, Journal of cardiovascular pharmacology.

[100]  J. Demirovic.  Public Health Aspects of Out-of-Hospital Sudden Cardiac Arrest Among Elderly African-Americans. , 1997, The American journal of geriatric cardiology.

[101]  Jan A Staessen,et al.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension , 1997, The Lancet.

[102]  J. Breyer,et al.  Effects of Blood Pressure Control on Progressive Renal Disease in Blacks and Whites , 1997 .

[103]  G. Bray,et al.  A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. , 1997, The New England journal of medicine.

[104]  B. Psaty,et al.  Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. , 1997, JAMA.

[105]  G. Bakris,et al.  Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. , 1997, Hypertension.

[106]  Detection.  The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) , 1997 .

[107]  A. Hall,et al.  Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators. , 1997, European heart journal.

[108]  W. Cushman,et al.  Use of the factorial design and quadratic response surface models to evaluate the fosinopril and hydrochlorothiazide combination therapy in hypertension. , 1997, American journal of hypertension.

[109]  D. Reda,et al.  Lessons from combination therapy in Veterans Affairs Studies. Department of Veterans Affairs Cooperative Study Group on antihypertensive agents. , 1996, American journal of hypertension.

[110]  W. Elliott.  Higher incidence of discontinuation of angiotensin converting enzyme inhibitors due to cough in black subjects , 1996, Clinical pharmacology and therapeutics.

[111]  S. Leurgans,et al.  Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. , 1996, Kidney international.

[112]  G. Mensah,et al.  Use of β ‐ Adrenergic Receptor Blockers in Blacks , 1996 .

[113]  N. Brown,et al.  Increased sensitivity to bradykinin among African Americans. , 1996, The Journal of allergy and clinical immunology.

[114]  C. Law,et al.  Is blood pressure inversely related to birth weight? The strength of evidence from a systematic review of the literature , 1996, Journal of hypertension.

[115]  P. Whelton,et al.  Appointment attendance, pill counts, and achievement of goal blood pressure in the African American Study of Kidney Disease and Hypertension Pilot Study. , 1996, Controlled clinical trials.

[116]  W A Ray,et al.  Black Americans have an increased rate of angiotensin converting enzyme inhibitor‐associated angioedema , 1996, Clinical pharmacology and therapeutics.

[117]  M. Weir,et al.  Hypertension in African Americans: a paradigm of metabolic disarray. , 1996, Seminars in nephrology.

[118]  R. Ames.  A comparison of blood lipid and blood pressure responses during the treatment of systemic hypertension with indapamide and with thiazides. , 1996, The American journal of cardiology.

[119]  P. Whelton,et al.  Blood pressure and end-stage renal disease in men. , 1996, The New England journal of medicine.

[120]  G. Mensah,et al.  Use of beta-adrenergic receptor blockers in blacks. , 1996, Journal of clinical pharmacology.

[121]  E. Aliot,et al.  A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. , 1995, The New England journal of medicine.

[122]  W. Frishman,et al.  Comparison of Amlodipine and Benazepril Monotherapy to Amlodipine Plus Benazepril In Patients with Systemic Hypertension: A Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group Study , 1995, Journal of clinical pharmacology.

[123]  M. Weir.  Salt intake and hypertensive renal injury in African-Americans. A therapeutic perspective. , 1995, American journal of hypertension.

[124]  T. Louis,et al.  Long-term effects of antihypertensive agents on proteinuria and renal function. , 1995, Archives of internal medicine.

[125]  V. Froelicher,et al.  Exercise standards. A statement for healthcare professionals from the American Heart Association. Writing Group. , 1995, Circulation.

[126]  K. Koury,et al.  A Multifactorial Trial Design to Assess Combination Therapy in Hypertension: Treatment With Bisoprolol and Hydrochlorothiazide , 1994 .

[127]  A Fournier,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1994, The New England journal of medicine.

[128]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.

[129]  C. Lewis,et al.  Treatment of Mild Hypertension Study: Final Results , 1993 .

[130]  J. Cutler,et al.  Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. , 1993, JAMA.

[131]  T. Lüscher,et al.  Efficacy and Safety of Various Combination Therapies Based on a Calcium Antagonist in Essential Hypertension: Results of a Placebo‐Controlled Randomized Trial , 1993, Journal of cardiovascular pharmacology.

[132]  S. Yusuf,et al.  Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.

[133]  G. Striker.  Modification of diet in renal disease. , 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[134]  V. Froelicher,et al.  Exercise standards. A statement for health professionals from the American Heart Association. , 1990, Circulation.

[135]  B. Massie,et al.  A Comparison of the Efficacy and Safety of a β-Blocker, a Calcium Channel Blocker, and a Converting Enzyme Inhibitor in Hypertensive Blacks , 1990 .

[136]  D E Manyari,et al.  Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. , 1990, The New England journal of medicine.

[137]  S. Glasser,et al.  Safety and efficacy of amlodipine added to hydrochlorothiazide therapy in essential hypertension. , 1989, American journal of hypertension.

[138]  Jeremiah Stamler,et al.  Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. Intersalt Cooperative Research Group. , 1988 .

[139]  L. Haywood.  Coronary heart disease mortality/morbidity and risk in blacks. I: Clinical manifestations and diagnostic criteria: the experience with the Beta Blocker Heart Attack Trial. , 1984, American heart journal.

[140]  G. Berenson,et al.  Racial differences of parameters associated with blood pressure levels in children--the Bogalusa heart study. , 1979, Metabolism: clinical and experimental.

[141]  W. Kannel,et al.  A general cardiovascular risk profile: the Framingham Study. , 1976, The American journal of cardiology.